---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-011571"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:20:09.489204+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics closes $100M senior secured loan facility; repays prior debt

## Summary
- Secured $100M loan; $60M funded, $20M available later, $20M contingent on FDA approval of arimoclomol for Niemann-Pick disease Type C.
- Interest rate is 3-month SOFR plus 7.00% (floor 4.00%); steps down to 6.00% or 6.50% based on net product sales thresholds.
- Proceeds refinanced Nantahala note (repaid April 8, 2024), pay fees, and fund Olpruva and arimoclomol development/commercialization.
- Loan matures 5 years from April 5, 2024; prepayment premiums and final payment premium of 3% of initial principal apply.

## SEC filing metadata
- accession: 0001437749-24-011571
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924011571/0001437749-24-011571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924011571/zvra20240409_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-011571
- JSON: https://secwatch.observer/filing/0001437749-24-011571.json
- Plain text: https://secwatch.observer/filing/0001437749-24-011571.txt

## Key facts
- Debt Financings
  ZEVRA THERAPEUTICS, INC. incurred credit facility of $100.0 million with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP at 3-Month Term SOFR plus 7.00% per annum maturing fifth anniversary of the Closing Date.
  - Instrument: credit facility
  - Principal: $100.0 million
  - Counterparty: HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP
  - Rate: 3-Month Term SOFR plus 7.00% per annum
  - Maturity: fifth anniversary of the Closing Date
  - Event: incurrence
  source text: the Lenders provided a senior secured loan facility to the Company in the aggregate principal amount of $100.0 million (the “Debt Financing”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924011571/0001437749-24-011571-index.htm
- Material Agreements
  ZEVRA THERAPEUTICS, INC. entered into Credit Agreement with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP as lenders valued at $100.0 million (effective 2024-04-05).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP as lenders
  - Value: $100.0 million
  - Effective: 2024-04-05
  source text: On April 5, 2024 (the "Closing Date"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or the "Company"), as the borrower, entered into a credit agreement (the "Credit Agreement") among the Company, Acer Therapeutics, Inc., a Delaware corporation ("Acer"), Epyon Therapeutics, Inc., a Delaware corporation ("Epyon"), and Zevra Denmark A/S, a public limited liability company organized under the laws of Denmark (together with Acer and Epyon, collectively, the "Guarantors"), HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP as lenders (collectively, the "Lenders"), and Alter Domus (US) LLC, as administrative agent (the "Administrative Agent").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924011571/0001437749-24-011571-index.htm
- Material Agreements
  ZEVRA THERAPEUTICS, INC. terminated Note Purchase Agreement with Nantahala Capital Management, LLC (effective 2024-04-04).
  - Action: termination
  - Agreement: notes offering
  - Counterparty: Nantahala Capital Management, LLC
  - Effective: 2024-04-04
  source text: On April 4, 2024, in connection with the Debt Financing, the Company delivered to Nantahala Capital Management, LLC ("NCM"), certain of its affiliates and certain other parties (collectively with NCM, "Nantahala") a payoff letter in connection with its repayment of amounts outstanding under the Note Purchase Agreement with Nantahala (the "Note Purchase Agreement"), dated August 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924011571/0001437749-24-011571-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.